Skip to main content
SpringerLink
Log in

Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Abnormal involuntary dyskinetic movements in schizophrenia patients have been documented for more than 140 years. Clinicians should distinguish between two kinds of disturbances—spontaneous dyskinetic movements and movements induced by psychotropic medications—which may look familiar clinically. As a modern term, tardive dyskinesia (TD) is a potentially permanent neurological hyperkinetic movement disorder that occurs after months or years of taking psychotropic drugs. Several distinct forms of TD exist, specifically tardive akathisia, tardive blepharospasm, tardive dystonia, tardive gait, tardive myoclonus, tardive tremor, and tardive tics, and they have different pathophysiologies and treatment. The pathogenesis of TD remains unclear, and the pathophysiology is complex and multifactorial. Moreover, there is solid evidence of a genetic predisposition to TD. This article summarizes recent relevant publications concerning TD and the most recent studies regarding treatment of this disorder with antioxidative agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Khot V, Wyatt RJ. Not all that moves is tardive dyskinesia. Am J Psychiatry. 1991;148:661–6.

    PubMed  CAS  Google Scholar 

  2. Owens DGC. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge: Cambridge University Press; 1999.

    Book  Google Scholar 

  3. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61 Suppl 4:10–4.

    PubMed  Google Scholar 

  4. Waddington JL, Crow TJ. Abnormal involuntary movements and psychosis in the preneuroleptic era and in medicated patients: implications for the concept of tardive dyskinesia. In: Wolf ME, Mosnaim AD, editors. Tardive dyslinesia: biological mechanisms and clinical aspects. Washington: American Psychiatric Press; 1988. p. 51–66.

    Google Scholar 

  5. Crow TJ, Cross AJ, Johnstone EC, et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol. 1982;2:336–40.

    Article  PubMed  CAS  Google Scholar 

  6. Kraepelin E. Dementia praecox and paraphrenia. Barclay, M. (trans). Huntington: Krieger, 1971.

  7. Fish F. Leonhard’s classification of schizophrenia. J Ment Sci. 1958;104:943–71.

    PubMed  CAS  Google Scholar 

  8. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28:550–3.

    PubMed  CAS  Google Scholar 

  9. Sigwald J, Bouttier D, Raymondeaud C, Piot C. 4 cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics. Rev Neurol (Paris). 1959;100:751–5.

    CAS  Google Scholar 

  10. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964;40:10–27.

    Article  PubMed  CAS  Google Scholar 

  11. Detweiler MB, Kalafat N, Kim KY. Drug-induced movement disorders in older adults: an overview for clinical practitioners. Consult Pharm. 2007;22:149–65.

    Article  PubMed  Google Scholar 

  12. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am. 2005;28:255–74. x.

    Article  PubMed  Google Scholar 

  13. Brion S, Plas J, Chevalier JF, Dussaux P. Senile dyskinesias and tardive dyskinesias. Encephale 1988;14 Spec No:215–219

    Google Scholar 

  14. Lauterbach EC, Carter WG, Rathke KM, et al. Tardive dyskinesia—diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service. Schizophr Bull. 2001;27:601–13.

    PubMed  CAS  Google Scholar 

  15. Skidmore F, Weiner WJ, Burke R. Neuroleptic-induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell; 2005. p. 257–84.

    Chapter  Google Scholar 

  16. DeLeon ML, Jankovic J. Clinical features and management of tardive dyskinesias, tardive myoclonus, tardive tremor, and tardive tourettism. In: Sethi K, editor. Drug induced movement disorders. New York: Marcel Dekker, Inc.; 2004. p. 77–109.

    Google Scholar 

  17. Lerner V, Libov I, Kaptsan A, et al. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;44:20–8.

    PubMed  Google Scholar 

  18. Skidmore F, Reich SG. Tardive dystonia. Curr Treat Options Neurol. 2005;7:231–6.

    Article  PubMed  Google Scholar 

  19. Miodownik C, Lerner V, Witztum E. Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. Isr J Psychiatry Relat Sci 2011 (in press).

  20. • Brasic JR, Bronson B. Tardive dyskinesia. Access: 2010, http://emedicine.medscape.com/article/1151826-overview. This is an updated review regarding TD.

  21. • Factor SA, Leffler JB, Murray CF. Drug-induced movement disorders: a clinical review. Access: 2009, http://cme.medscape.com/viewarticle/586881. This is also an updated review regarding TD.

  22. Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone, Elsevier; 2007.

    Google Scholar 

  23. van Harten PN, Matroos GE, Van Os J. The course of tardive dystonia in Afro Caribbean patients, a population-based study: the Curacao extrapyramidal syndromes study: VII. Schizophr Res. 2008;98:79–83.

    Article  PubMed  Google Scholar 

  24. Lee Y, Yeh WC, Chong MY, et al. Venlafaxine and tardive blepharospasm: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1139–40.

    Article  PubMed  CAS  Google Scholar 

  25. Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J Neuropsychiatry Clin Neurosci. 2007;19:86–7.

    Article  PubMed  Google Scholar 

  26. Sachdev P. Tardive blepharospasm. Mov Disord. 1998;13:947–51.

    Article  PubMed  CAS  Google Scholar 

  27. Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura; 1992. p. 167–98.

    Google Scholar 

  28. Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–51.

    Article  PubMed  CAS  Google Scholar 

  29. Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7:53–7.

    Article  PubMed  CAS  Google Scholar 

  30. Tarsy D, Indorf G. Tardive tremor due to metoclopramide. Mov Disord. 2002;17:620–1.

    Article  PubMed  Google Scholar 

  31. Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110:198–201.

    Article  PubMed  Google Scholar 

  32. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61 Suppl 4:5–9.

    PubMed  CAS  Google Scholar 

  33. Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. 2007;153:271–5.

    Article  PubMed  CAS  Google Scholar 

  34. Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet. 2009;19:106–7.

    Article  PubMed  Google Scholar 

  35. • Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 2009; 11: 405–415. This is a review regarding the effect of dopamine D2- and D3-receptor genes (DRD2, DRD3, and HTR2C) on the risk of TD.

    PubMed  Google Scholar 

  36. Souza RP, Remington G, Chowdhury NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol. 2010;20:688–94.

    Article  PubMed  CAS  Google Scholar 

  37. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003;39:19–49.

    Article  CAS  Google Scholar 

  38. Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry. 2006;18:133–43.

    Article  PubMed  Google Scholar 

  39. Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1130–8.

    Article  PubMed  CAS  Google Scholar 

  40. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68:1648–54.

    Article  PubMed  CAS  Google Scholar 

  41. Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:1031–7.

    Article  PubMed  CAS  Google Scholar 

  42. Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res. 2005;74:263–70.

    Article  PubMed  Google Scholar 

  43. Dalgalarrondo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci. 1994;244:272–7.

    Article  PubMed  CAS  Google Scholar 

  44. Bai YM, Chou KH, Lin CP, et al. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study. Schizophr Res. 2009;109:167–81.

    Article  PubMed  Google Scholar 

  45. McCreadie RG, Thara R, Padmavati R, et al. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry. 2002;59:332–6.

    Article  PubMed  Google Scholar 

  46. Niznikiewicz MA, Kubicki M, Shenton ME. Recent structural and functional imaging findings in schizophrenia. Curr Opin Psychiatry. 2003;16:123–47.

    Article  Google Scholar 

  47. Szymanski S, Gur RC, Gallacher F, et al. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism. Neuropsychopharmacology. 1996;15:567–75.

    Article  PubMed  CAS  Google Scholar 

  48. Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia: shortened left caudate T2. Biol Psychiatry. 1990;28:1027–36.

    Article  PubMed  CAS  Google Scholar 

  49. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151–6.

    Article  PubMed  Google Scholar 

  50. Tenback DE, van Harten PN, Slooff CJ, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010;24:1031–5.

    Article  PubMed  CAS  Google Scholar 

  51. DeLeon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia. A naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2007;257:169–72.

    Article  Google Scholar 

  52. •• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010; 71: 463–474. This prospective cohort study found that current users of typical and atypical antipsychotics had similar incidences of TD.

    Article  PubMed  CAS  Google Scholar 

  53. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98.

    Article  PubMed  Google Scholar 

  54. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–312.

    Article  PubMed  CAS  Google Scholar 

  55. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11:169–82.

    Article  PubMed  CAS  Google Scholar 

  56. Fehr C, Dahmen N, Klawe C, et al. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001;21:248–9.

    Article  PubMed  CAS  Google Scholar 

  57. Kabes J, Sikora J, Stary O, et al. Effectiveness of piracetam in tardive dyskinesia—double-blind cross-over controlled trial with a placebo. Cesk Psychiatr. 1983;79:339–45.

    PubMed  CAS  Google Scholar 

  58. Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf. 2007;6:241–50.

    Article  PubMed  CAS  Google Scholar 

  59. Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol. 2006;26:215–6.

    Article  PubMed  Google Scholar 

  60. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21:1219–21.

    Article  PubMed  Google Scholar 

  61. Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546–54.

    Article  PubMed  CAS  Google Scholar 

  62. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65 Suppl 9:25–8.

    PubMed  CAS  Google Scholar 

  63. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42:281–5.

    Article  PubMed  CAS  Google Scholar 

  64. Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev. 2011;33:289–93.

    Article  PubMed  Google Scholar 

  65. Schaeffer MC, Cochary EF, Sadowski JA. Subtle abnormalities of gait detected early in vitamin B6 deficiency in aged and weanling rats with hind leg gait analysis. J Am Coll Nutr. 1990;9:120–7.

    PubMed  CAS  Google Scholar 

  66. Dakshinamurti K, Paulose CS, Viswanathan M, et al. Neurobiology of pyridoxine. Ann NY Acad Sci. 1990;585:128–44.

    Article  PubMed  CAS  Google Scholar 

  67. Goodman LS, Gilman A. The pharmacologic basis of therapeutics, vol. II. 8th ed. New York: McGraw-Hill; 1992.

    Google Scholar 

  68. Dreyfus PM, Geel SE. Vitamins and nutritional deficiencies. In: Siegel GJ, Alberts RW, Agranoff BW, Katzman R, editors. Basic neurochemistry. Boston: Little Brown; 1981. p. 661–79.

    Google Scholar 

  69. Viswanathan M, Siow YL, Paulose CS, Dakshinamurti K. Pineal indoleamine metabolism in pyridoxine-deficient rats. Brain Res. 1988;473:37–42.

    Article  PubMed  CAS  Google Scholar 

  70. Cabrini L, Bergami R, Fiorentini D, et al. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int. 1998;46:689–97.

    PubMed  CAS  Google Scholar 

  71. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158:1511–4.

    Article  PubMed  CAS  Google Scholar 

  72. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47–62.

    Article  PubMed  CAS  Google Scholar 

  73. Tarsy D. Tardive dyskinesia. Curr Treat Options Neurol. 2000;2:205–14.

    Article  PubMed  Google Scholar 

  74. Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry. 1998;43:868–72.

    Article  PubMed  CAS  Google Scholar 

  75. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57:167–73.

    PubMed  CAS  Google Scholar 

  76. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836–41.

    Article  PubMed  CAS  Google Scholar 

  77. Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry. 1992;149:391–3.

    PubMed  CAS  Google Scholar 

  78. Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry. 1997;41:114–6.

    Article  PubMed  CAS  Google Scholar 

  79. Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacother. 1999;33:1195–202.

    Article  PubMed  CAS  Google Scholar 

  80. Barak Y, Swartz M, Shamir E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry. 1998;10:101–5.

    PubMed  CAS  Google Scholar 

  81. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001:CD000209.

  82. Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61:835–45.

    Article  PubMed  CAS  Google Scholar 

  83. Reiter RJ, Maestroni GJ. Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. J Mol Med. 1999;77:36–9.

    Article  PubMed  CAS  Google Scholar 

  84. Shamir E, Barak Y, Plopsky I, et al. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry. 2000;61:556–8.

    Article  PubMed  CAS  Google Scholar 

  85. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58:1049–52.

    Article  PubMed  CAS  Google Scholar 

  86. Melatonin Natural Medicines Comprehensive Database, 2010;www.naturaldatabase.com

  87. Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother. 2003;37:1128–31.

    Article  PubMed  Google Scholar 

  88. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J Neurochem. 2000;74:2268–77.

    Article  PubMed  CAS  Google Scholar 

  89. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25–58.

    Article  PubMed  CAS  Google Scholar 

  90. Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001;62:878–83.

    Article  PubMed  CAS  Google Scholar 

  91. Mirnikjoo B, Brown SE, Kim HF, et al. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem. 2001;276:10888–96.

    Article  PubMed  CAS  Google Scholar 

  92. Ikemoto A, Nitta A, Furukawa S, et al. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci Lett. 2000;285:99–102.

    Article  PubMed  CAS  Google Scholar 

  93. Sarsilmaz M, Songur A, Ozyurt H, et al. Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats’ corpus striatum. Prostaglandins Leukot Essent Fatty Acids. 2003;69:253–9.

    Article  PubMed  CAS  Google Scholar 

  94. Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006;84:112–20.

    Article  PubMed  Google Scholar 

  95. Puri BK. High-resolution magnetic resonance imaging sinc-interpolation-based subvoxel registration and semi-automated quantitative lateral ventricular morphology employing threshold computation and binary image creation in the study of fatty acid interventions in schizophrenia, depression, chronic fatigue syndrome and Huntington’s disease. Int Rev Psychiatry. 2006;18:149–54.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Be’er-Sheva Mental Health Center, Ben-Gurion University of the Negev, P.O. Box 4600, Be’er-Sheva, 84170, Israel

    Vladimir Lerner & Chanoch Miodownik

Authors
  1. Vladimir Lerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chanoch Miodownik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir Lerner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lerner, V., Miodownik, C. Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment. Curr Psychiatry Rep 13, 295–304 (2011). https://doi.org/10.1007/s11920-011-0202-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-011-0202-6

Keywords

Search

Navigation